Paul Tudor Jones’s Haemonetics HAE Stock Holding History

Paul Tudor Jones’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,300	Closed	-$210K	–	3445
2025 Q1	$210K	Buy	+3,300	New	+$224K	﹤0.01%	2841

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paul Tudor Jones's HAE Position: Q1 2026 in Review

Paul Tudor Jones sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 45,776 shares — an estimated $3.67M sold.

Paul Tudor Jones first reported a position in HAE in Q2 2013 and held it in 22 quarters. The position peaked at $3.67M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Paul Tudor Jones reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 45,776 Haemonetics shares in Q1 2026, an estimated $3.67M.
Paul Tudor Jones first reported a position in Haemonetics in Q2 2013 and held it in 22 quarters.
Paul Tudor Jones's Haemonetics position peaked at $3.67M in Q4 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.